drugset
drugset / Trial / NCT05099822

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants

NCT05099822 ↗

Phase 1 Terminated 84 enrolled Celgene Corporation
RandomizedSequentialDouble-blindTreatment

Summary

This study aims to evaluate the safety, tolerability, of CC-97489

Timeline

Start
2020-03-13
Primary completion
2022-07-11
Completion
2022-07-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986368 Unknown — —

Indications

No indication recorded.